Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Through ClinFAST, Selkirk is focused on meeting critical clinical timelines. Selkirk Pharma CEO Colleen Dixon said: “In ...

Insilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

With a strong cash position of A$159.26 million, the company is well-funded for future operations and clinical trials. Immutep received regulatory approval for its pivotal TACTI-004 Phase III ...

The three phases of schizophrenia are the prodromal ... sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations.

Investing.com -- Shares of CARGO Therapeutics , Inc. (NASDAQ: CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 clinical trial for firicabtagene autoleucel, citing ...